menu
    • menu

    Company profile for Avrobio

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    AVROBIO, Inc., a leader in lentiviral-based gene therapies, is a clinical stage company developing disruptive therapies that have the potential to transform patients’ lives in a single dose. The aim of AVROBIO’s gene therapy programs is to deliver lasting and meaningful benefits for patients with genetic diseases by restoring normal gene function and enzyme/protein production.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AvrobioUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    One Kendall Square, Building 300, Suite 201 Cambridge, MA 02139
    Telephone
    Telephone
    617.914.8420
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.avrobio.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/avrobio/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/avrobio

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Tectonic Closes AVROBIO Merger And Raises $130.7M In Concurrent Placement
    Tectonic Closes AVROBIO Merger And Raises $130.7M In Concurrent Placement

    20 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240620882931/en

    BUSINESSWIRE
    20 Jun 2024
    Share Share
    AVROBIO and Tectonic Therapeutic Announce Merger
    AVROBIO and Tectonic Therapeutic Announce Merger

    30 Jan 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240130047688/en

    BUSINESSWIRE
    30 Jan 2024
    Share Share
    Avrobio stops programs, halves head count and searches for exit
    Avrobio stops programs, halves head count and searches for exit

    12 Jul 2023

    // Nick Paul Taylor FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/avrobio-stops-programs-halves-headcount-and-searches-exit

    Nick Paul Taylor FIERCE BIOTECH
    12 Jul 2023
    Share Share
    AVROBIO to Explore Strategic Alternatives
    AVROBIO to Explore Strategic Alternatives

    12 Jul 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230712243011/en

    BUSINESSWIRE
    12 Jul 2023
    Share Share
    Novartis Buys Avrobio Gene Therapy for $88 Million
    Novartis Buys Avrobio Gene Therapy for $88 Million

    31 May 2023

    // CONTRACT PHARMA

    https://www.contractpharma.com/contents/view_breaking-news/2023-05-31/avrobio-sells-cystinosis-gene-therapy-for-875-million/?widget=listSection

    CONTRACT PHARMA
    31 May 2023
    Share Share
    Novartis to buy Avrobio gene therapy for $88M, ending M&A rumor
    Novartis to buy Avrobio gene therapy for $88M, ending M&A rumor

    23 May 2023

    // Nick Paul Taylor FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/novartis-buy-avrobio-gene-therapy-88m-leaving-rest-biotech-shelf

    Nick Paul Taylor FIERCE BIOTECH
    23 May 2023
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search